EICHORCondition: Diffuse Large B Cell Lymphoma · Sponsor: University Hospital Southampton NHS Foundation Trust
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy. All patients will receive one cycle of R-CHOP. Two thirds of patients (Arm B) will go on to receive a further 5 cycles (every 21 days) of R-CHOP with Acalabrutinib. Acalabrutinib will be taken orally twice daily continuously in 21 day cycles. One third of patients (Arm A) will continue with 5 cycles of R-CHOP. Patients will be followed up initially for 24 months and then for disease status and survival until 114 progression events have been observed.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Colchester General Hospital | Colchester, Essex, United Kingdom | — |
| East Kent Hospitals NHS Foundation Trust | Canterbury, Kent, United Kingdom | — |
| Monklands Hospital | Airdrie, United Kingdom | — |
| Victoria Hospital | Blackpool, United Kingdom | — |
| University Hospital Dorset NHS Foundation Trust (Bournemouth and Poole Hospitals) | Bournemouth, United Kingdom | — |
| Queens Hospital | Burton-on-Trent, United Kingdom | — |
| Addenbrooke's Hospital | Cambridge, United Kingdom | — |
| Royal Derby Hospital | Derby, United Kingdom | — |
| Royal Devon and Exeter Hospital | Exeter, United Kingdom | — |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | — |
| Ipswich Hospital | Ipswich, United Kingdom | — |
| St James Hospital | Leeds, United Kingdom | — |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04546620